Lenalidomide: Clinical Trials

1,111 trials of Lenalidomide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

504 completed, 146 terminated, 144 active not recruiting, 125 recruiting. 682 Phase 2, 370 Phase 1, 175 Phase 3, 20 Phase 4, 14 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 2682Completed 312, Terminated 87, Recruiting 82, Active not recruiting 77, Unknown 68, Withdrawn 28, Not yet recruiting 25, Enrolling by invitation 2, Suspended 1
Phase 1370Completed 188, Terminated 70, Active not recruiting 41, Recruiting 24, Unknown 22, Withdrawn 16, Not yet recruiting 7, Suspended 2
Phase 3175Completed 65, Active not recruiting 43, Recruiting 29, Unknown 13, Not yet recruiting 12, Terminated 9, Withdrawn 4
Phase 420Completed 5, Unknown 5, Recruiting 3, Not yet recruiting 2, Terminated 2, Withdrawn 2, Active not recruiting 1
Not applicable14Completed 6, Unknown 3, Recruiting 2, Terminated 2, Not yet recruiting 1
Early Phase 19Completed 3, Recruiting 2, Terminated 2, Unknown 2

Follow Lenalidomide: new trials by email Literature Review of Lenalidomide trials Research Report on Lenalidomide

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome
Biospecimen Collection, Computed Tomography, Cosibelimab - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome
Phase 1Not yet recruitingCity of Hope Medical Center142027-05-162026-11-09
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia
Phase 2RecruitingNational Cancer Institute (NCI)742027-04-202026-11-18
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Anitocabtagene Autoleucel, Isatuximab, Bortezomib - Newly Diagnosed Multiple Myeloma
Phase 3Not yet recruitingKite, A Gilead Company7502027-02-012026-11-16
Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The treatment regimen consists of a combination of Tafasitamab, Lenalidomide, and CIK_D332 - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 1Not yet recruitingIstituto Oncologico Veneto IRCCS142027-01-312026-11-03
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma
Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma
Phase 3Not yet recruitingKite, A Gilead Company6002027-01-012026-10-21
Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma
Zilovertamab vedotin Intravenous (IV) Infusion - 1.75 mg/kg, Lenalidomide - Peripheral T-Cell Lymphoma Refractory
Phase 2Not yet recruitingOlivia Newton-John Cancer Research Institute252027-01-012026-11-03
Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma
Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM)
Phase 2 / Phase 3Not yet recruitingAlliance for Clinical Trials in Oncology9202026-12-232026-10-22
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Ramantamig, Daratumumab, Bortezomib - Multiple Myeloma
Phase 3Not yet recruitingJanssen Research & Development, LLC10002026-12-142026-11-04
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)
MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma
Phase 2 / Phase 3Not yet recruitingMerck Sharp & Dohme LLC4702026-12-132026-11-05
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma
Phase 1 / Phase 2Not yet recruitingUniversitätsklinikum Hamburg-Eppendorf2202026-12-012026-05-20
Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy
Epcoritamab, Lenalidomide - Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL)
Phase 2Not yet recruitingThe Lymphoma Academic Research Organisation552026-12-012026-09-10
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib - Multiple Myeloma
Phase 3RecruitingPrECOG, LLC.5002026-12-012026-11-12
Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Tafasitamab, Lenalidomide, Rituximab - Diffuse Large B Cell Lymphoma (DLBCL)
Phase 2Not yet recruitingSun Yat-sen University292026-12-012026-11-16
Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma
Lenalidomide, Bruton's tyrosine kinase inhibitor, Chidamide - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences872026-11-012026-11-04
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
CM336 (BCMA/CD3 bispecific antibody), Daratumumab, Lenalidomide - Multiple Myeloma
Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China242026-10-152026-10-26
F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma
F182112 Plus Isatuximab and Lenalidomide - Multiple Myeloma (MM), Transplant-eligible Patients
Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China102026-10-012026-09-18
Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL
Zanubrutinib, Lenalidomide - Primary Central Nervous System Lymphoma (PCNSL), Zanubrutinib
Phase 2RecruitingXiaohui Ren332026-09-252026-11-10
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
AZD0120, Cyclophosphamide, Fludarabine - Newly Diagnosed Multiple Myeloma (NDMM)
Phase 3RecruitingAstraZeneca7502026-09-242026-10-21
CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia
CM336, Isatuximab, Bortezomib - Plasma Cell Leukemia (PCL)
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China242026-09-152026-09-18
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Ramantamig, Daratumumab, Lenalidomide - Multiple Myeloma
Phase 3RecruitingJanssen Research & Development, LLC10002026-09-092026-11-03

Showing 20 of 1111. Sign in to see all of them.

Conditions studied

Multiple Myeloma (444)  ·  Lymphoma, Large B-Cell, Diffuse (102)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (89)  ·  Lymphoma, Follicular (82)  ·  Recurrence (79)  ·  Lymphoma (62)  ·  Lymphoma, Mantle-Cell (60)  ·  Neoplasms, Plasma Cell (59)  ·  Myelodysplastic Syndromes (52)  ·  Lymphoma, B-Cell, Marginal Zone (47)  ·  Lymphoma, Non-Hodgkin (47)  ·  Leukemia, Myeloid, Acute (34)  ·  Leukemia (32)  ·  Lymphoma, B-Cell (24)  ·  Neoplasms (24)

Sponsors

Celgene (63)  ·  M.D. Anderson Cancer Center (60)  ·  National Cancer Institute (NCI) (57)  ·  Mayo Clinic (29)  ·  Celgene Corporation (23)  ·  Memorial Sloan Kettering Cancer Center (22)  ·  Ruijin Hospital (21)  ·  Janssen Research & Development, LLC (20)  ·  Bristol-Myers Squibb (15)  ·  Dana-Farber Cancer Institute (14)  ·  H. Lee Moffitt Cancer Center and Research Institute (13)  ·  The First Affiliated Hospital with Nanjing Medical University (13)  ·  Massachusetts General Hospital (12)  ·  PETHEMA Foundation (12)  ·  The Lymphoma Academic Research Organisation (12)

Countries

United States (640)  ·  China (155)  ·  France (149)  ·  Spain (128)  ·  Germany (122)  ·  Italy (115)  ·  United Kingdom (94)  ·  Canada (85)  ·  Australia (80)  ·  Belgium (73)  ·  Japan (57)  ·  Poland (57)  ·  South Korea (57)  ·  Austria (56)  ·  Czechia (54)

Top investigators

Robert Knight, MD (11)  ·  Ravi Vij, M.D. (5)  ·  Shaji K. Kumar, MD (5)  ·  Hani Hassoun, MD (4)  ·  James R Berenson, MD (4)  ·  Paul Richardson, MD (4)

Results publications

PMID 29358183, PMID 33357481, PMID 39319495, PMID 23834234, PMID 35285981, PMID 35985959, PMID 31221778, PMID 35549810, PMID 38062124, PMID 18799726, PMID 18824593, PMID 19901114, PMID 21273172, PMID 23194056, PMID 26181891, PMID 27531679, PMID 27705267, PMID 28314699, PMID 28379796, PMID 28651604, PMID 28803351, PMID 30561775, PMID 32325490, PMID 34182226, PMID 34289038, PMID 34549906, PMID 34587246, PMID 34780623, PMID 34826409, PMID 35132679, PMID 35660812, PMID 35787017, PMID 35952327, PMID 36882409, PMID 37369099, PMID 37990162, PMID 38023148, PMID 38031761, PMID 38048552, PMID 38084760, PMID 38649340, PMID 38652812, PMID 39229471, PMID 39293025, PMID 39321347, PMID 39374535, PMID 40802906, PMID 41915772, PMID 17021321, PMID 17893227

NIH funding

2023 (34), 2009 (17), P30CA015083 (16), U10CA180820 (11), U10CA180821 (9), 2015 (8), 2019 (8), U10CA021115 (8), U10CA031946 (8), 2008 (7), 2025 (7), P30CA016058 (7), U01CA076576 (7), U10CA180888 (7), U10CA032102 (6)